Adalgisa Condoluci

Years Active: 2022-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Clara Deambrogi, Silvia Rasi, Francesco Autore, Michele Merli, Roberta Mattarucchi, Gaby Fahrni, Lydia Scarfo', Daniela Gussetti, Pietro Bulian, Annagiulia Zanatta, Valeria Spina, Alessio Bruscaggin, Katia Pini, Deborah Piffaretti, Maria Cristina Pirosa, Matin Salehi, Joyce Marques de Almeida, Jakob Passweg, Franco Cavalli, Emanuele Zucca, Bernhard Gerber, Georg Stussi, Valter Gattei, Paolo Ghia, Michael Gregor, Francesco Passamonti, Luca Laurenti, Gianluca Gaidano, Alessandra Tedeschi, Davide Rossi, Adalgisa Condoluci
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. Hematological oncology (2022)
Adalgisa Condoluci, Davide Rossi
Mechanisms of resistance to venetoclax. Blood 140 (20) (2022)
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, Lodovico Terzi di Bergamo, Valeria Spina, Alessio Bruscaggin, Clara Deambrogi, Riccardo Moia, Marina Deodato, Gaby Fahrni, Roberta Mattarucchi, Michele Merli, Bernhard Gerber, Georg Stussi, Francesco Passamonti, Michael Gregor, Alessandra Tedeschi, Gianluca Gaidano, Davide Rossi, Luca Ceriani
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. Hematological oncology (2022)

Adalgisa Condoluci.css-eqlu8i{font-size:small;padding-left:4px;}